Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain  Jacques R. Caldwell, MD, Ronald J. Rapoport,

Published byHandoko Hartanto Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain  Jacques R. Caldwell, MD, Ronald J. Rapoport,"— Presentation transcript:

1 Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain  Jacques R. Caldwell, MD, Ronald J. Rapoport, MD, Jeffrey C. Davis, MD, Howard L. Offenberg, MD, Howard W. Marker, MD, Sanford H. Roth, MD, William Yuan, PhD, Lise Eliot, PhD, Najib Babul, PharmD, Pia Mikkelsen Lynch, MD  Journal of Pain and Symptom Management  Volume 23, Issue 4, Pages (April 2002) DOI: /S (02)

2 Fig. 1 Patient disposition in the double-blind trial.
Journal of Pain and Symptom Management  , DOI: ( /S (02) )

3 Fig. 2 Sleep measures in the double-blind trial. Data are presented as Mean ± SE scored on a 100-mm VAS scale (0–100mm), with the exception of duration of sleep each night which is scored on a 12-pt scale (1 to 12 hr). For quality of sleep each night, positive values indicate an improvement. For trouble falling asleep due to Pain, Need for Sleep Medication, and Awakenings During the Night and Morning due to Pain, negative values indicate an improvement. *Statistically significant (p ≤ 0.05) difference versus placebo. †Statistically significant (p ≤ 0.05) difference versus MSC twice daily. Journal of Pain and Symptom Management  , DOI: ( /S (02) )

4 Fig. 3 Patient disposition in the open-label trial.
Journal of Pain and Symptom Management  , DOI: ( /S (02) )

5 Fig. 4 Efficacy in the open-label trial. Efficacy data are presented as Mean changes ± SE from baseline (Week 4). Dose data presented as Mean ± SE, which represents the dose at the time of the efficacy assessments. *Statistically significant differences in efficacy assessments from baseline (Week 4) for both Avinza QAM and QPM (p ≤ 0.05). WOMAC OA Index Pain (0–500 mm), Overall Arthritis Pain Intensity (0–100 mm) and WOMAC Physical Function (0–1,700 mm), WOMAC Stiffness (0–200 mm). Journal of Pain and Symptom Management  , DOI: ( /S (02) )

Download ppt "Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain  Jacques R. Caldwell, MD, Ronald J. Rapoport,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain  Xiaowei.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain  Xiaowei.
Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys  Emmanuel Maheu, MD, François.

Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys  Emmanuel Maheu, MD, François.
Clinical Trial Results with OROS® Hydromorphone

Clinical Trial Results with OROS® Hydromorphone
Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain  Richard L. Rauck, MD, Mark S. Wallace,

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain  Richard L. Rauck, MD, Mark S. Wallace,
A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations  Mary E. Lynch,

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations  Mary E. Lynch,
The Impact of Chronic Pain on Life in the Household

The Impact of Chronic Pain on Life in the Household
Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study  Liliane.

Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study  Liliane.
Short-term placebo response in trials of patients with symptomatic osteoarthritis: differences between hip and knee  S. Reiter-Niesert, M. Boers, J. Detert 

Short-term placebo response in trials of patients with symptomatic osteoarthritis: differences between hip and knee  S. Reiter-Niesert, M. Boers, J. Detert 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Dr L. S. Kim, N. D. , Dr L. J. Axelrod, N. D. , Dr P. Howard, M. D

Dr L. S. Kim, N. D. , Dr L. J. Axelrod, N. D. , Dr P. Howard, M. D
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced.

A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced.
Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine  Rainer Sabatowski, MD, Stefan.

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine  Rainer Sabatowski, MD, Stefan.
Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,
The adequacy of the minimum data set assessment of pain in cognitively impaired nursing home residents  Jiska Cohen-Mansfield, PhD, ABPP  Journal of Pain.

The adequacy of the minimum data set assessment of pain in cognitively impaired nursing home residents  Jiska Cohen-Mansfield, PhD, ABPP  Journal of Pain.
Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate.

Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate.

Similar presentations

Ads by Google